P.001 T-436

F-716

Customer No. 28880		CENTRAL FAX CENTER	Confirmation No. 2435					
Linder the Pananuark Reduction Act of 1995	. no nemoni	NOV 0 4 2004 U.S. Paten	Approved for use through 04/30/2003. OMB 0651-0031 t and Trademark Office; U.S. DEPARTMENT OF COMMERCE in of information unless it displays a valid OMB control number.					
TRANSMITTAL		Application Number	08/812,508					
		Filing Date	March 7, 1997					
FORM		First Named Inventor	Janak Khimchand Padia, et al.					
(to be used for all correspondence after inklai filling)		Art Unit	1624					
		Examiner Name	Deepak R. Rao					
Total Number of Pages in This Submission	24	Attorney Docket Number	5117-C1-01-MG					
ENCLOSURES (Check all that apply)								
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement Certified Copy of Priority Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53	Remar AUTHO	RIZATION TO CHARGE T	After Allowance Communication to a Technology Center (TC) Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter Other Enclosure(s) (please identify below): HE FEE AND ANY ADDITIONAL FEES AS VERPAYMENT TO DEPOSIT ACCOUNT					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT								
or Mendi Ganjetzaden	,	•						
Individual Signature	(4 7							
Date 11/4/2004	• (
CERTIFICATE OF TRANSMISSION/MAILING								

CERTIFICATE OF TRANSMISSION/MAILING							
I hereby cartify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mall in an envelope addressed to:Commissioner for Patents, P.O.Box 1450, Nexandria, VA 22313-1450 on the case November 4, 2004							
Typed or printed	Inja Cho	$\overline{}$					
Signature	- An	ka	()/		Date	11/4/2004	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is powered by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducine this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commiscoe, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

USPTO Fax No.

703-872-9306

ov-04-2004 04:58pm From- PATENT PFIZER ANN ARBOR MI 7346222928 T-436 P.002 . F-716

Confirmation No. 2435

RECEIVED CENTRAL FAX CENTER

5117-C1-01-MG

NOV 0 4 2004

PAPER NO.

IN THE UNITED STATES PATENT & TRADEMARK OFFICE

APPLICANT: Janak Khimchand Padia, et al. EXAMINER: Deepak R. Rao

SERIAL NO. : 08/812,508 ART UNIT : 1624

FOR : Novel Heterocycles as Cholecystokinin (CCK) Ligands

: March 17, 1997

AMENDMENT AND RESPONSE

Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

FILED

This paper is in response to the Office Action mailed August 4, 2004. No new matter is introduced by way of this submission. Reconsideration of the captioned application in light of these amendments and the following remarks is respectfully requested.

Kindly amend this application as follows:

Amendments to the Claims are reflected in the listing of claims, which begins on page 2 of this paper.

Remarks begin on page 22 of this paper.